Atuka is delighted to welcome Ian Lennox, a successful and pioneering leader in the biopharmaceutical research industry, as a non-executive member of our Board of Directors. 

Over the last decade, Atuka has successfully expanded its offerings from a traditional base in Parkinson’s to establish contract research services in gene therapy, cognition, and other challenging neurological diseases. As we now look to further build on that growth with a fresh and ambitious strategic plan, we are excited about Ian’s contribution to that process, and the thoughtful, energetic, and innovative approach to executive leadership he has shown throughout his extensive career. As CEO for companies such as Drug Royalty (DRI), Phoenix Life Sciences, MDS, and Ricerca Biotechnology, or at the more than a dozen other companies for whom he has served as an executive or director (Monsanto, Celerion, Bracket, Lakepharma, YPrime, CHS), he’s shown exactly what it takes to innovate in the biotechnology sector. Atuka is honoured to have his expertise at our boardroom table.

+ Follow Atuka on LinkedIn